Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

The Independent UK

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Investors Business Daily

Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story

Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

A $1.3 Billion Reason to Buy Eli Lilly Stock Now

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion.

Investors Business Daily

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.

Weight-Loss Drugs Pose Long-Term Threat To McDonald's: Analyst

McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Investors Business Daily

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

Is Eli Lilly and Company Stock Underperforming the Dow?

Is Eli Lilly and Company Stock Underperforming the Dow?

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

5 High-Potential Stocks That Could Have Your Investments Rising Quickly

5 High-Potential Stocks That Could Have Your Investments Rising Quickly

The stock market doesn’t hand out guarantees. But every so often, a few companies show signs of powerful upward movement due to innovation, market shifts,...

The TGA has approved donanemab for Alzheimer’s disease. How does this drug work and who will be able to access it?

The TGA has approved donanemab for Alzheimer’s disease. How does this drug work and who will be able to access it?

This week, Australia’s Therapeutic Goods Administration (TGA) approved a drug called donanemab for people in the early stages of Alzheimer’s disease.

The Conversation

Australia approves new drug to treat early Alzheimer’s disease

Australia approves new drug to treat early Alzheimer’s disease

Kisunla is first new treatment registered by TGA in 25 years but could cost patients more than $80,000 and less than one in five will be eligible

The Guardian - AU

Get all your
news in one place.

100’s of premium titles.
One news app.

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’

Cramer explains why this pharmaceutical company is a buy as it outperforms a key rival.

Investors Business Daily

Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

International Business Times

Ozempic-maker Novo Nordisk Says CEO To Step Down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

Get all your
news in one place.

100’s of premium titles.
One news app.

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

Despite Trump’s executive order to cut drug prices, Eli Lilly’s stock surged, showing strong resilience and impressive gains amidst regulatory concerns.

Investors Business Daily

Top Funds Make Mad Dash For These 9 Stocks — Plus Palantir

The latest list of new buys by the best mutual funds shows investors loaded up on DoorDash, Netflix, Robinhood, Palantir stock and more.

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Despite lagging behind the broader market over the past year, Eli Lilly continues to enjoy a highly bullish outlook from Wall Street analysts, who remain confident in the company’s long-term growth potential.

The Guardian - UK

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

Investors Business Daily

Mutual Funds Gobble Up Eli Lilly Stock, Ge Vernova And A Wrestling Name

Eli Lilly stock is in a long consolidation pattern and below a critical moving average.

People

136,277 stories

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Executive Order

Alzheimer Disease

Places

298,792 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play